[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Tahir Misbah, Chief Financial Officer of Maze Therapeutics, Inc. (MAZE), was granted a stock option for 325,000 shares with an exercise price of $15.32. The Form 4 reports the option award dated 09/02/2025 and shows 325,000 shares beneficially owned following the transaction as a direct holding. The option includes a vesting schedule: 1/4 of the award vests on September 2, 2026, then 1/48th of the total award vests monthly thereafter, subject to continued service. The filing is signed by an attorney-in-fact on behalf of the reporting person and reports the transaction under Section 16.

Positive

• Grant of 325,000 stock options to the CFO is explicitly disclosed
• Exercise price of $15.32 is clearly stated in the filing
• Vesting schedule provided: 1/4 vests on September 2, 2026, then 1/48th monthly thereafter, subject to continued service
• Beneficial ownership after transaction: 325,000 shares reported as direct beneficial ownership

Negative

• None.

Insights

Financial Analyst

TL;DR: CFO granted 325,000 options at $15.32 with multi-year vesting; routine executive compensation, not an immediate liquidity event.

The grant is a standard long-term equity award designed to align executive incentives with shareholder value over time. The exercise price of $15.32 is stated in the filing and the option is recorded as a direct beneficial holding of 325,000 shares following the transaction. The vesting schedule front-loads no immediate full vesting, with a one-year cliff (1/4 on 09/02/2026) and monthly vesting thereafter, which retains retention incentives. No cash proceeds, sales, or other transactions are reported.

Corporate Governance Expert

TL;DR: Award follows typical governance practice: time-based vesting tied to continued service, disclosed under Section 16.

The Form 4 provides required disclosure for an insider equity award to the CFO. The structured vesting (one-year cliff then monthly vesting) is common and intended to promote retention. The filing identifies the reporting person, relationship to the issuer, and shows the award as a direct holding. The document includes the signature of an attorney-in-fact, fulfilling signature requirements for the report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tahir Misbah

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.32	09/02/2025		A		325,000		(1)	09/01/2035	Common Stock	325,000	$0	325,000	D

Explanation of Responses:

1. The option shall vest as to 1/4th of the total award on September 2, 2026, and thereafter shall vest as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who received the equity award reported on the Form 4 for MAZE?

The award was granted to Tahir Misbah, who is identified as the Chief Financial Officer of Maze Therapeutics, Inc.

What was granted and at what price on the MAZE Form 4?

A stock option for 325,000 shares with an exercise price of $15.32 was reported.

What is the vesting schedule for the 325,000-option award?

The option vests 1/4 on September 2, 2026 and thereafter 1/48th of the total award vests monthly, subject to continued service.

How many shares does the reporting person beneficially own after the transaction?

The filing reports 325,000 shares beneficially owned following the reported transaction, held directly.

When was the transaction dated and when was the Form 4 signed?

The transaction date is 09/02/2025, and the Form 4 is signed by an attorney-in-fact on 09/02/2025.